STOCK TITAN
  1. Home
  2. News
  3. CGEM

Cullinan Oncology Inc - CGEM STOCK NEWS

Welcome to our dedicated news page for Cullinan Oncology (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cullinan Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cullinan Oncology's position in the market.

News
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Rhea-AI Summary
Cullinan Therapeutics, formerly Cullinan Oncology, is strategically expanding into autoimmune diseases with a focus on systemic lupus erythematosus. The company's CLN-978 clinical development will target autoimmune diseases, showcasing promising results in B cell depletion and clinical activity. Cullinan Therapeutics will host a virtual investor event on April 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
News
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Rhea-AI Summary
Cullinan Therapeutics announces an oversubscribed $280 million private placement, extending cash runway into 2028. The financing includes new and existing leading life sciences institutional investors. Cullinan to host a virtual investor event on April 16 at 8:00 am ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
News
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) reported strong financial results for Q4 and full year 2023. The company received FDA clearance for an IND to evaluate CLN-619 in multiple myeloma, with plans to present clinical data in Q2 2024. They are also exploring the development of CLN-978 for autoimmune disorders. Cash and investments stood at $468.3 million as of December 31, 2023, providing runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
earnings
News
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Rhea-AI Summary
Cullinan Oncology, Inc. (CGEM) to initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, marking the first MICA/B antibody clinical study in hematologic malignancies. The FDA has cleared the Investigational New Drug (IND) application for CLN-619, a potential first-in-class humanized IgG1 monoclonal antibody. The company plans to start a Phase 1 trial to evaluate CLN-619 in patients with multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
clinical trial
-
News
Cullinan Oncology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Cullinan Oncology, Inc. (CGEM) announces participation in investor conferences to discuss Gynecologic Cancers and financial updates. The Chief Medical Officer and Chief Financial Officer will be presenting at the TD Cowen and Leerink Partners conferences, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
-
News
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced that CEO Nadim Ahmed will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The presentation will be available via live webcast on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
News
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the dosing of the first patient with CLN-617 in a Phase 1 clinical trial. CLN-617 is a first-in-class cytokine therapy designed for intratumoral injection, combining human IL-2, IL-12, a collagen binding domain, and a size-enhancing domain. The therapy aims to promote retention of the cytokines in the injected tumor and potentially provide enhanced safety and efficacy. In pre-clinical models, CLN-617 stimulated a broad systemic immune response, leading to the regression of non-injected distal tumors and the generation of a memory T cell response that enhanced long-term survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
clinical trial
-
News
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) reported on recent business highlights and financial results for Q3 2023. They expect to provide clinical data updates on three novel targeted oncology programs in 2024 and have a cash and investment position of $482 million as of September 30, 2023, expected to provide runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
earnings
-
News
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Rhea-AI Summary
Cullinan Oncology, Inc. will present data across four immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The data supports the proposed mechanism of action and demonstrates clinical activity in patients with tumors not typically responsive to checkpoint inhibitor therapy. The presentations will cover CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bispecific immune activator; CLN-978, a CD19XCD3 bispecific T cell engager; and CLN-617, a fusion protein harnessing IL-2 and IL-12 cytokines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
conferences
News
Cullinan Oncology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Cullinan Oncology, a biopharmaceutical company, will participate in upcoming investor conferences including the TD Cowen 7th Annual Fall Oncology Innovation Summit, the Stifel 2023 Healthcare Conference, and the Evercore ISI HealthCONx Conference. Webcasts of these events will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
conferences
Stock CGEM logo
Cullinan Oncology Inc

Nasdaq:CGEM

CGEM Rankings

#2707 Ranked by Market Cap
#4141 Ranked by Stock Gains
N/A Ranked by Dividends

CGEM Stock Data

717.90M
25.88M
6.4%
95.24%
3.33%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cambridge

About CGEM

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.